← Leaderboards
Robert T Abraham
Duke University
$4,888,060
Attributed
$4,888,060
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $232.4K · FY2005–08$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$14,295,716 · 7
By mechanism
P30$9,836,073 · 2
R01$3,606,454 · 3
U19$853,189 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- John P Chute$16,426,438
- Barton F Haynes$531,570,874
- Michael Barry Kastan$65,974,699
- Shirish Shenolikar$2,788,778
- Edward C Halperin$685,042
Others in their field
Top investigators on “Enzyme Activity”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$47,808,754
- Susan Abushakra · Alzheon, Inc.$47,265,244
- David Heimbrook · Leidos Biomedical Research, Inc.$45,964,082
- Stuart L Schreiber · Harvard University (Medical School)$40,631,496
- Keith O Hodgson · Stanford University$37,935,767
Research focus
Enzyme ActivityBiological Signal TransductionPhosphorylationTissue /Cell CultureEnzyme MechanismSirolimusCell CycleCell LineAntineoplasticsNeoplastic CellTranslation FactorEnzyme InhibitorsGrowth InhibitorsDrug Screening /EvaluationCell TransformationNeoplasm /Cancer GeneticsNeoplasm /Cancer PharmacologyPhosphatidylinositol 3 KinaseCell Growth RegulationBioassayCell ProliferationDna RepairCombinatorial ChemistryDrug Discovery /Isolation
Grant awards (26)
Developmental Pilot Project 2$151,170
P30 · FY2008 · CA · contact PI
Developmental Pilot Project 2$140,274
P30 · FY2007 · CA · contact PI
Developmental Pilot Project 2$47,014
P30 · FY2006 · CA · contact PI
KINASE TARGETS IN HYPOXIC CANCER CELLS$186,754
U19 · FY2005 · CA
Developmental Pilot Project 2$45,644
P30 · FY2005 · CA
CANCER CENTER SUPPORT GRANT$3,400,001
P30 · FY2004 · CA
Roles of ATM and ATR Kinases in DNA Damage Responses$396,495
R01 · FY2004 · CA
Cellular Pharmacology of Rapamycin$336,000
R01 · FY2004 · CA
Developmental Pilot Project 2$44,315
P30 · FY2004 · CA
CANCER CENTER SUPPORT GRANT$3,043,791
P30 · FY2003 · CA
Roles of ATM and ATR Kinases in DNA Damage Responses$396,495
R01 · FY2003 · CA
SIGNAL TRANSDUCTION FROM THE T CELL ANTIGEN RECEPTOR$348,480
R01 · FY2003 · GM
Cellular Pharmacology of Rapamycin$336,000
R01 · FY2003 · CA
CANCER CENTER SUPPORT GRANT$2,963,864
P30 · FY2002 · CA
Roles of ATM and ATR Kinases in DNA Damage Responses$396,495
R01 · FY2002 · CA
SIGNAL TRANSDUCTION FROM THE T CELL ANTIGEN RECEPTOR$348,480
R01 · FY2002 · GM
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$250,404
U19 · FY2002 · CA
SIGNAL TRANSDUCTION FROM THE T CELL ANTIGEN RECEPTOR$348,480
R01 · FY2001 · GM
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$250,404
U19 · FY2001 · CA
CELLULAR PHARMACOLOGY OF RAPAMYCIN$147,767
R01 · FY2001 · CA
CELLULAR PHARMACOLOGY OF RAPAMYCIN$69,643
R01 · FY2001 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2001 · CA
SIGNAL TRANSDUCTION FROM THE T CELL ANTIGEN RECEPTOR$271,040
R01 · FY2000 · GM
CELLULAR PHARMACOLOGY OF RAPAMYCIN$211,079
R01 · FY2000 · CA
CELL CYCLE TARGETS FOR ANTICANCER DRUGS$165,627
U19 · FY2000 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2000 · CA